Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience (NCT07777965)
A Phase 4, Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, Four-Way Crossover Study Evaluating the Abuse Potential of Two Doses of Gabapentin Taken Orally in Healthy, Non-Drug-Dependent Participants With Sedative Drug Use Experience
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the present study is to assess prospectively the abuse potential of gabapentin compared to placebo and alprazolam in healthy non-drug-dependent recreational sedative drug users under fasted condition.
Who can join: Review the eligibility criteria below.
Location: Dr. Vince Clinical Research — Overland Park, Kansas
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Dr. Vince Clinical Research — Overland Park, Kansas
📞 Contact the Study Coordinator
Phone: (+44) 1304626895
Email: Dik.Ng@viatris.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Healthy Non-dependent, Recreational Sedative Users clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.